date:Nov 20, 2018
The theory is that exposing people to small doses of peanut protein over time will gradually increase their tolerance.
In this 2018 trial, Aimmune said 67 percent of the participants were able to tolerate the equivalent of about two peanuts by the end of the study. About 20 percent dropped out of the trial and 12 percent were due to treatment-related issues.
The company expects to file for U.S. Food and Drug Administration approval by the end of 2018, and for approval in Europe in early 2019.